NCT00525057 · ADVERSE EVENTS

Adverse events

Dalteparin in Preventing DVT in Participants With Cancer · Source last updated 2021-01-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: 4 weeks after surgery
Other-event reporting threshold: 5%

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Interventional (Dalteparin, Metastatic) Received dalteparin 5000 units daily postop, patients with metastatic disease.	1 / 25	1 / 25	0 / 25
Interventional (Dalteparin, Sarcoma) Received dalteparin 5000 units daily postop, patients with primary sarcomas.	0 / 25	4 / 25	0 / 25

Group identifiers: EG000: Interventional (Dalteparin, Metastatic) · EG001: Interventional (Dalteparin, Sarcoma)

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Vascular disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
1
num At Risk
25
group Id
EG001
num Affected
0
num At Risk
25
term
Thromboembolic event

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Surgical and medical procedures
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
1
num At Risk
25
group Id
EG001
num Affected
4
num At Risk
25
term
Seroma
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Surgical and medical procedures
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
25
group Id
EG001
num Affected
3
num At Risk
25
term
Wound infection

Complete source fields

event Groups

deaths Num Affected
0
deaths Num At Risk
25
description
Received dalteparin 5000 units daily postop, patients with metastatic disease.
id
EG000
other Num Affected
1
other Num At Risk
25
serious Num Affected
1
serious Num At Risk
25
title
Interventional (Dalteparin, Metastatic)
deaths Num Affected
0
deaths Num At Risk
25
description
Received dalteparin 5000 units daily postop, patients with primary sarcomas.
id
EG001
other Num Affected
4
other Num At Risk
25
serious Num Affected
0
serious Num At Risk
25
title
Interventional (Dalteparin, Sarcoma)

frequency Threshold

other Events

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Surgical and medical procedures
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
1
num At Risk
25
group Id
EG001
num Affected
4
num At Risk
25
term
Seroma
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Surgical and medical procedures
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
25
group Id
EG001
num Affected
3
num At Risk
25
term
Wound infection

serious Events

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Vascular disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
1
num At Risk
25
group Id
EG001
num Affected
0
num At Risk
25
term
Thromboembolic event

time Frame

4 weeks after surgery

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice